Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Elisabetta Pierdomenico"'
Autor:
Alessandra Sperotto, Maria Teresa Lupo Stanghellini, Jacopo Peccatori, Roberta De Marchi, Simona Piemontese, Giulia Ciotti, Marco Basso, Elisabetta Pierdomenico, Paolo Fiore, Fabio Ciceri, Michele Gottardi
Publikováno v:
Frontiers in Oncology, Vol 13 (2024)
Therapy-related myeloid neoplasms (t-MNs), which develop after cytotoxic, radiation, or immunosuppressive therapy for an unrelated disease, account for 7%–8% of acute myeloid leukemia (AML). Worse outcomes and consequently shortened survival are as
Externí odkaz:
https://doaj.org/article/302e7d393baa409ebf4de45ad722255a
Autor:
Massimiliano Bonifacio, Mario Tiribelli, Maria Cristina Miggiano, Elisabetta Abruzzese, Gianni Binotto, Luigi Scaffidi, Maddalena Cordioli, Daniela Damiani, Eros Di Bona, Malgorzata Monika Trawinska, Ilaria Tanasi, Maria Vittoria Dubbini, Vanessa Velotta, Giulia Ceccarelli, Elisabetta Pierdomenico, Mariella Lo Schirico, Gianpietro Semenzato, Marco Ruggeri, Renato Fanin, Evelina Tacconelli, Giovanni Pizzolo, Mauro Krampera
Publikováno v:
Cancer Medicine, Vol 10, Iss 18, Pp 6310-6316 (2021)
Abstract Background Patients with hematological malignancies are at an increased risk of SARS‐CoV‐2 disease (COVID‐19) and adverse outcome. However, a low mortality rate has been reported in patients with chronic myeloid leukemia (CML). Preclin
Externí odkaz:
https://doaj.org/article/4e846c090a3840e789287e4d5b68960c
Autor:
Alessandra Sperotto, Maria Teresa Bochicchio, Giorgia Simonetti, Francesco Buccisano, Jacopo Peccatori, Simona Piemontese, Elisabetta Calistri, Giulia Ciotti, Elisabetta Pierdomenico, Roberta De Marchi, Fabio Ciceri, Michele Gottardi
Publikováno v:
Biomedicines, Vol 11, Iss 2, p 359 (2023)
It has now been ascertained that acute myeloid leukemias—as in most type of cancers—are mixtures of various subclones, evolving by acquiring additional somatic mutations over the course of the disease. The complexity of leukemia clone architectur
Externí odkaz:
https://doaj.org/article/8b94f3eb53354eb7b5911ce9d77db2a6
Autor:
Maria Vittoria Dubbini, Mariella Lo Schirico, Gianpietro Semenzato, Massimiliano Bonifacio, Mario Tiribelli, Luigi Scaffidi, Maddalena Cordioli, Giulia Ceccarelli, Eros Di Bona, Renato Fanin, Vanessa Velotta, Maria Cristina Miggiano, Gianni Binotto, Malgorzata Monika Trawinska, Evelina Tacconelli, Mauro Krampera, Daniela Damiani, Ilaria Tanasi, Elisabetta Abruzzese, Giovanni Pizzolo, Marco Ruggeri, Elisabetta Pierdomenico
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 18, Pp 6310-6316 (2021)
Cancer Medicine, Vol 10, Iss 18, Pp 6310-6316 (2021)
Background Patients with hematological malignancies are at an increased risk of SARS‐CoV‐2 disease (COVID‐19) and adverse outcome. However, a low mortality rate has been reported in patients with chronic myeloid leukemia (CML). Preclinical evid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf0a18c9ca6e471c6888783d5029b26b
http://europepmc.org/articles/PMC8446554
http://europepmc.org/articles/PMC8446554
Autor:
Mario Tiribelli, Massimiliano Bonifacio, Eros Di Bona, Giovanni Pizzolo, Evelina Tacconelli, Renato Fanin, Malgorzata Monika Trawinska, Mauro Krampera, Giulia Ceccarelli, Daniela Damiani, Maria Vittoria Dubbini, Luigi Scaffidi, Marco Ruggeri, Elisabetta Pierdomenico, Maddalena Cordioli, Vanessa Velotta, Maria Cristina Miggiano, Gianpietro Semenzato, Gianni Binotto, Mariella Loschirico
Publikováno v:
Blood
Background. Clinical course of the novel Coronavirus (SARS-CoV-2) Disease 2019 (COVID-19) is extremely heterogeneous, and infected individuals may be asymptomatic or develop acute respiratory manifestations. Elderly people and patients with pre-exist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dce6d6addfb5851e9a3878254f9dbae8
https://doi.org/10.1182/blood-2020-140032
https://doi.org/10.1182/blood-2020-140032